Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by canadafanon Oct 05, 2024 12:39pm
288 Views
Post# 36254562

Weekend updates & thanks to notable

Weekend updates & thanks to notable

Hello all
first , my hats off to notable.He/ she has put out a lot of effort to detail the various advantages & applications of Pelareorep. That being clinical information as to why & how Pela works & why better co- therapy with some drugs & not others.
As always, i direct readers to the oncolyitics biotech web site.
They have a great presentation designed to " try" to explain the various in- place proven results & a focus to the future opportunities.
i say " try"
Cancer is a very complicated disease. Almost every type, has sub types.
and
our bodies react differently to treatments. Simply put not all drugs/ therapies work for everyone.
So just for starters , we have a very complex disease, then add in unlimited variables with the patients.
Leaving drug developments with unimaginable complex outcomes. 

Drug companies after getting approval, need to market, manufacture & distribute product XYZ.
Pelareorep has full scale in- place approved production capacity.
The production cost is minimal. 
Where the cost is , getting to the approval.
Right now, Onc has fast track designation for Pelareorep to be used for Pancreatic cancer & one type of breast cancer.
They do not yet have marketing approval.
The recent news release clearly indicates they are in- process of defining & starting a potential enabling study, with accelerated approval indications.
What does that mean?
First, understand ALL of ONCs activities are moderated alongside the  FDA.
The pancreatic cancer trials are alongside Roche.
Those who enjoy bashing mangemet need to please inform Roche of your extream intelligence, as they obviously missed something? 

Respectfully , Roche would not risk their good name , or their lead cancer product alongside oncolytics without massive due diligence.
Then again the upcoming additional arm added to the Gobblet studies ( G.I. Cancers), was the direct result  of a competive application.
From that Onc was granted $5million, 
moving forward the upcoming enabling study will be managed by CGAR, a global pancreatic cancer agency.
what does accelerated approval mean?
Once the studies are started, They can use previous study data & if certain milestones met, product approval can be granted, prior to completion.
Saving years of study time & obviously $$$$.
simple put, Onc is we'll set to move forward.
yes they still need a $$ partner for the MBc trial.
or a complete buyout.
Shareholder value? As notable pointed out the company that just did a pharma deal with $850mill upfront, was not even a listed company.
The value is in the potential market of the product.
onc is a lot closer to that now than ever.
Slow, complex....absolutely.
should they get approved , yes $ billios
take care

 

 

<< Previous
Bullboard Posts
Next >>